Microbix Biosystems Inc. (MBXBF)
USD 0.27
(10.2%)
USD 0.27
(10.2%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 6.64 Million CAD | 14.11% |
| 2022 | 5.82 Million CAD | -24.71% |
| 2021 | 7.73 Million CAD | 25.27% |
| 2020 | 6.17 Million CAD | -11.66% |
| 2019 | 6.98 Million CAD | 11.67% |
| 2018 | 6.25 Million CAD | -13.98% |
| 2017 | 7.27 Million CAD | -1.33% |
| 2016 | 7.37 Million CAD | 2.52% |
| 2015 | 7.19 Million CAD | 21.52% |
| 2014 | 5.91 Million CAD | 13.2% |
| 2013 | 5.22 Million CAD | -24.41% |
| 2012 | 6.91 Million CAD | 15.41% |
| 2011 | 5.99 Million CAD | -0.12% |
| 2010 | 6 Million CAD | 7.58% |
| 2009 | 5.57 Million CAD | 42.84% |
| 2008 | 3.9 Million CAD | 100.82% |
| 2007 | 1.94 Million CAD | 51.0% |
| 2006 | 1.28 Million CAD | 101.25% |
| 2005 | 639.93 Thousand CAD | 2.88% |
| 2004 | 622.03 Thousand CAD | 45.96% |
| 2003 | 426.15 Thousand CAD | 23.52% |
| 2002 | 345 Thousand CAD | -37.84% |
| 2001 | 555 Thousand CAD | -26.0% |
| 2000 | 750 Thousand CAD | 7.14% |
| 1999 | 700 Thousand CAD | -12.5% |
| 1998 | 800 Thousand CAD | 60.0% |
| 1997 | 500 Thousand CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 6.35 Million CAD | -5.34% |
| 2024 Q2 | 6.71 Million CAD | 0.56% |
| 2024 Q1 | 6.67 Million CAD | 0.49% |
| 2023 FY | 6.64 Million CAD | 14.11% |
| 2023 Q2 | 6.54 Million CAD | 9.65% |
| 2023 Q3 | 6.56 Million CAD | 0.33% |
| 2023 Q1 | 5.96 Million CAD | 2.46% |
| 2023 Q4 | 6.64 Million CAD | 1.23% |
| 2022 FY | 5.82 Million CAD | -24.71% |
| 2022 Q2 | 6.35 Million CAD | 3.26% |
| 2022 Q3 | 5.83 Million CAD | -8.1% |
| 2022 Q1 | 6.15 Million CAD | -20.45% |
| 2022 Q4 | 5.82 Million CAD | -0.27% |
| 2021 Q1 | 6.14 Million CAD | -0.51% |
| 2021 Q2 | 6.33 Million CAD | 3.07% |
| 2021 Q3 | 6.33 Million CAD | 0.06% |
| 2021 FY | 7.73 Million CAD | 25.27% |
| 2021 Q4 | 7.73 Million CAD | 22.09% |
| 2020 Q1 | 7.33 Million CAD | 5.01% |
| 2020 FY | 6.17 Million CAD | -11.66% |
| 2020 Q3 | 6.13 Million CAD | -1.57% |
| 2020 Q4 | 6.17 Million CAD | 0.64% |
| 2020 Q2 | 6.23 Million CAD | -15.07% |
| 2019 FY | 6.98 Million CAD | 11.67% |
| 2019 Q1 | 6.54 Million CAD | 4.54% |
| 2019 Q2 | 6.77 Million CAD | 3.53% |
| 2019 Q3 | 7.12 Million CAD | 5.19% |
| 2019 Q4 | 6.98 Million CAD | -1.92% |
| 2018 FY | 6.25 Million CAD | -13.98% |
| 2018 Q2 | 6.19 Million CAD | -1.79% |
| 2018 Q3 | 6.43 Million CAD | 3.9% |
| 2018 Q4 | 6.25 Million CAD | -2.81% |
| 2018 Q1 | 6.31 Million CAD | -13.26% |
| 2017 Q4 | 7.27 Million CAD | 5.61% |
| 2017 Q2 | 6.98 Million CAD | 3.76% |
| 2017 FY | 7.27 Million CAD | -1.33% |
| 2017 Q1 | 6.73 Million CAD | -8.73% |
| 2017 Q3 | 6.88 Million CAD | -1.35% |
| 2016 Q2 | 7.43 Million CAD | 1.33% |
| 2016 Q4 | 7.37 Million CAD | -0.87% |
| 2016 Q1 | 7.33 Million CAD | 2.02% |
| 2016 Q3 | 7.43 Million CAD | 0.04% |
| 2016 FY | 7.37 Million CAD | 2.52% |
| 2015 FY | 7.19 Million CAD | 21.52% |
| 2015 Q1 | 6.51 Million CAD | 10.06% |
| 2015 Q4 | 7.19 Million CAD | 8.73% |
| 2015 Q2 | 6.52 Million CAD | 0.24% |
| 2015 Q3 | 6.61 Million CAD | 1.31% |
| 2014 Q4 | 5.91 Million CAD | -5.13% |
| 2014 Q1 | 5.36 Million CAD | 2.61% |
| 2014 FY | 5.91 Million CAD | 13.2% |
| 2014 Q3 | 6.23 Million CAD | 0.67% |
| 2014 Q2 | 6.19 Million CAD | 15.51% |
| 2013 Q2 | 7.03 Million CAD | 2.3% |
| 2013 Q4 | 5.22 Million CAD | -25.32% |
| 2013 Q3 | 7 Million CAD | -0.5% |
| 2013 Q1 | 6.87 Million CAD | -0.57% |
| 2013 FY | 5.22 Million CAD | -24.41% |
| 2012 FY | 6.91 Million CAD | 15.41% |
| 2012 Q4 | 6.91 Million CAD | 14.81% |
| 2012 Q3 | 6.02 Million CAD | -1.44% |
| 2012 Q2 | 6.11 Million CAD | 0.4% |
| 2012 Q1 | 6.08 Million CAD | 1.59% |
| 2011 Q2 | 6.29 Million CAD | 9.16% |
| 2011 FY | 5.99 Million CAD | -0.12% |
| 2011 Q4 | 5.99 Million CAD | -5.08% |
| 2011 Q3 | 6.31 Million CAD | 0.37% |
| 2011 Q1 | 5.76 Million CAD | -3.97% |
| 2010 Q3 | 5.72 Million CAD | 0.27% |
| 2010 Q2 | 5.7 Million CAD | 0.53% |
| 2010 Q1 | 5.67 Million CAD | 1.73% |
| 2010 Q4 | 6 Million CAD | 4.91% |
| 2010 FY | 6 Million CAD | 7.58% |
| 2009 FY | 5.57 Million CAD | 42.84% |
| 2009 Q3 | 5.48 Million CAD | 6.23% |
| 2009 Q4 | 5.57 Million CAD | 1.69% |
| 2009 Q1 | 3.92 Million CAD | 0.58% |
| 2009 Q2 | 5.16 Million CAD | 31.46% |
| 2008 Q2 | 1.92 Million CAD | -0.33% |
| 2008 Q1 | 1.93 Million CAD | -0.63% |
| 2008 FY | 3.9 Million CAD | 100.82% |
| 2008 Q4 | 3.9 Million CAD | 13.96% |
| 2008 Q3 | 3.42 Million CAD | 77.93% |
| 2007 Q4 | 1.94 Million CAD | 2.9% |
| 2007 FY | 1.94 Million CAD | 51.0% |
| 2007 Q1 | 1.61 Million CAD | 25.38% |
| 2007 Q2 | 1.9 Million CAD | 17.78% |
| 2007 Q3 | 1.88 Million CAD | -0.63% |
| 2006 Q4 | 1.28 Million CAD | 8.47% |
| 2006 FY | 1.28 Million CAD | 101.25% |
| 2006 Q2 | 1.18 Million CAD | 48.14% |
| 2006 Q1 | 799.77 Thousand CAD | 24.98% |
| 2006 Q3 | 1.18 Million CAD | 0.21% |
| 2005 Q1 | 592.32 Thousand CAD | -4.78% |
| 2005 Q2 | 575.49 Thousand CAD | -2.84% |
| 2005 FY | 639.93 Thousand CAD | 2.88% |
| 2005 Q4 | 639.93 Thousand CAD | 9.56% |
| 2005 Q3 | 584.07 Thousand CAD | 1.49% |
| 2004 Q3 | 639.62 Thousand CAD | 1.12% |
| 2004 Q2 | 632.56 Thousand CAD | 61.28% |
| 2004 Q4 | 622.03 Thousand CAD | -2.75% |
| 2004 FY | 622.03 Thousand CAD | 45.96% |
| 2004 Q1 | 392.22 Thousand CAD | -7.96% |
| 2003 Q4 | 426.15 Thousand CAD | -33.15% |
| 2003 Q2 | 650 Thousand CAD | -1.89% |
| 2003 Q1 | 662.5 Thousand CAD | 92.03% |
| 2003 FY | 426.15 Thousand CAD | 23.52% |
| 2003 Q3 | 637.5 Thousand CAD | -1.92% |
| 2002 Q3 | 447.5 Thousand CAD | -10.5% |
| 2002 FY | 345 Thousand CAD | -37.84% |
| 2002 Q2 | 500 Thousand CAD | -5.21% |
| 2002 Q1 | 527.5 Thousand CAD | -4.95% |
| 2002 Q4 | 345 Thousand CAD | -22.91% |
| 2001 Q1 | 712.5 Thousand CAD | -5.0% |
| 2001 FY | 555 Thousand CAD | -26.0% |
| 2001 Q3 | 607.58 Thousand CAD | -7.95% |
| 2001 Q4 | 555 Thousand CAD | -8.65% |
| 2001 Q2 | 660.08 Thousand CAD | -7.36% |
| 2000 FY | 750 Thousand CAD | 7.14% |
| 2000 Q1 | 600 Thousand CAD | -14.29% |
| 2000 Q4 | 750 Thousand CAD | -6.25% |
| 2000 Q3 | 800 Thousand CAD | -11.11% |
| 2000 Q2 | 900 Thousand CAD | 50.0% |
| 1999 Q2 | 700 Thousand CAD | 0.0% |
| 1999 Q4 | 700 Thousand CAD | 0.0% |
| 1999 Q3 | 700 Thousand CAD | 0.0% |
| 1999 Q1 | 700 Thousand CAD | -12.5% |
| 1999 FY | 700 Thousand CAD | -12.5% |
| 1998 Q4 | 800 Thousand CAD | 0.0% |
| 1998 FY | 800 Thousand CAD | 60.0% |
| 1998 Q3 | - CAD | -100.0% |
| 1998 Q2 | 500 Thousand CAD | 25.0% |
| 1998 Q1 | 400 Thousand CAD | -20.0% |
| 1997 Q2 | 600 Thousand CAD | 20.0% |
| 1997 Q3 | 500 Thousand CAD | -16.67% |
| 1997 Q1 | 500 Thousand CAD | 0.0% |
| 1997 FY | 500 Thousand CAD | 0.0% |
| 1997 Q4 | 500 Thousand CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bioxytran, Inc. | 1.92 Million USD | -245.212% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 83.872% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1553.687% |
| SQZ Biotechnologies Company | 27.47 Million USD | 75.81% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -185.703% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 84.679% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 77.676% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -600.783% |
| Marizyme, Inc. | 18.71 Million USD | 64.497% |
| Genus plc | 233.1 Million USD | 97.149% |
| Pharming Group N.V. | 171.54 Million USD | 96.126% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -648.293% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -394.597% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -786.043% |
| ContraFect Corporation | 2.88 Million USD | -130.66% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -359.465% |
| IMV Inc. | 28.88 Million USD | 76.993% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -17.443% |
| ONE Bio Corp. | 19.71 Million USD | 66.293% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 88.441% |
| Mesoblast Limited | 118.7 Million USD | 94.402% |
| MultiCell Technologies, Inc. | 202.58 USD | -3280246.036% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 79.924% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.409% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -954.685% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -440.991% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -61.218% |
| Biomind Labs Inc. | 735.54 Thousand USD | -803.46% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -119.594% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 48.87% |
| Skye Bioscience, Inc. | 4.61 Million USD | -43.986% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1747.412% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -126.773% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -4595.745% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -4804.769% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -13.187% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -25738.194% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -344.577% |
| Q BioMed Inc. | 4.1 Million USD | -61.687% |
| GB Sciences, Inc. | 1.75 Million USD | -277.724% |
| Alpha Cognition Inc. | 1.22 Million USD | -444.533% |
| CSL Limited | 12.18 Billion USD | 99.945% |
| Agentix Corp. | 50 Thousand USD | -13190.65% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 90.176% |
| Enzolytics Inc. | 996.33 Thousand USD | -566.975% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 6.49 Million USD | -2.378% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -2499.974% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -194.252% |
| argenx SE | 20 Million USD | 66.773% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 85.414% |
| HST Global, Inc. | 98.31 Thousand USD | -6658.943% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -2571.81% |
| Halberd Corporation | 150 Thousand USD | -4330.217% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 6.044% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -64890.954% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -145.332% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -177.151% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -2798.206% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -4370.33% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -3212.46% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | -202.077% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 67.309% |
| Kadimastem Ltd | 891.22 Thousand USD | -645.639% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | -41.047% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -2556.196% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 33.6 Thousand USD | -19674.222% |
| Cell Source, Inc. | 9.25 Million USD | 28.191% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -778.774% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -778.774% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -1272.196% |
| Itoco Inc. | 228.37 Thousand USD | -2809.805% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -3049.816% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -33.36% |
| International Stem Cell Corporation | 4.17 Million USD | -59.055% |
| CytoDyn Inc. | 30.07 Million USD | 77.905% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1788.697% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 15.021% |
| SYBLEU INC | 477.5 Thousand USD | -1291.691% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -5324.755% |
| Rebus Holdings, Inc. | 310 Thousand USD | -2043.653% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -40.336% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -10547.341% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -204.706% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 20.09% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 22.594% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -327.22% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -2379.599% |
| Neutra Corp. | 54.15 Thousand USD | -12170.709% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -263.133% |
| PureTech Health plc | 25.51 Million USD | 73.952% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -442.818% |
| IXICO plc | 472.02 Thousand USD | -1307.839% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 57.13% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 89.327% |
| CSL Limited | 12.18 Billion USD | 99.945% |
| Cellectis S.A. | 92.77 Million USD | 92.837% |